UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 
 
FORM 8-K

 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): September 5, 2017

 
 
PhaseRx, Inc.
(Exact name of registrant as specified in its charter)

 
 
Delaware	 	001-37772	 	20-4690620	
(State or other jurisdiction
of incorporation)	 	(Commission File Number)	 	(IRS Employer Identification No.)	
 
410 W. Harrison Street, Suite 300
Seattle, Washington	 	98119	
(Address of principal executive offices)	 	(Zip Code)	
 
Registrant’s telephone number, including area code: (206) 805-6300

(Former name or former address, if changed since last report)

 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 	¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
 	¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
 	¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
 	¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company   x
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   x

 

 
 
Item 5.02	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.	
 
On September 5, 2017, Shing-Yin (Helen) Tsui, the senior vice president, finance, secretary and principal accounting officer of PhaseRx, Inc. (the “Company”), notified the Company of her resignation from all positions with the Company, effective as of September 15, 2017. Upon effectiveness of Ms. Tsui’s resignation, Robert W. Overell, the Company’s president and chief executive officer, will replace Ms. Tsui as the secretary of the Company.

 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 	PhaseRx, Inc.	
 	 	 	
Date: September 8, 2017	By:   	/s/ Robert W. Overell	
 	 	Robert W. Overell, Ph.D.	
 	 	Chief Executive Officer